TriangleNCT02302807 · OUTCOME
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- mcg/mL
- Interval / dispersion
- Standard Deviation
- Time frame
- 30 minutes post dose on Day 1 of Cycles 1
What was measured
Cmax was measured for all participants that received at least one dose of Atezolizumab.
Analysis population: The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.
Groups in this outcome
Atezolizumab
Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
| Group | Source count |
|---|---|
| Atezolizumab | 467 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Atezolizumab | 334 | 125 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 125
- value
- 334
- denoms
- counts
- group Id
- OG000
- value
- 467
- units
- Participants
- description
- Cmax was measured for all participants that received at least one dose of Atezolizumab.
- dispersion Type
- Standard Deviation
- groups
- description
- Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
- id
- OG000
- title
- Atezolizumab
- param Type
- GEOMETRIC_MEAN
- population Description
- The PK-evaluable population is defined as patients who received atezolizumab treatment and had at least one measureable PK concentration.
- reporting Status
- POSTED
- time Frame
- 30 minutes post dose on Day 1 of Cycles 1
- title
- Maximum Observed Serum Atezolizumab Concentration (Cmax)
- type
- SECONDARY
- unit Of Measure
- mcg/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice